Angiotensin-converting enzyme 2: Enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy

Daniel Batlle, Jan Wysocki, Maria J. Soler, Keerthi Ranganath*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

77 Scopus citations

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase that degrades angiotensin II with high efficiency leading to the formation of angiotensin-(1-7). ACE2 within the kidneys is largely localized in tubular epithelial cells and in glomerular epithelial cells. Decreased glomerular expression of this enzyme coupled with increased expression of ACE has been described in diabetic kidney disease, both in mice and humans with type 2 diabetes. Moreover, both ACE2 genetic ablation and pharmacological ACE2 inhibition have been shown to increase albuminuria and promote glomerular injury. Studies using recombinant ACE2 have shown the ability of ACE2 to rapidly metabolize Ang II in vivo and form the basis for future studies to examine the potential of ACE2 amplification in the therapy of diabetic kidney disease and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)520-528
Number of pages9
JournalKidney international
Volume81
Issue number6
DOIs
StatePublished - Mar 2 2012

Keywords

  • angiotensin
  • diabetic nephropathy
  • renin-angiotensin system

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Angiotensin-converting enzyme 2: Enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy'. Together they form a unique fingerprint.

Cite this